A new publication from the laboratory of Dr. T R Santhoshkumar (Scientist, BRIC-RGCB) appeared in the journal "Biology Direct" and the title of the manuscript is "Estrogen receptor alpha dynamics and plasticity during endocrine resistance".

A new publication from the laboratory of Dr. Debanjan Bhowmik (Scientist, BRIC-RGCB) appeared in the journal " Langmuir" and the title of the manuscript is " Optimizing Branch Morphology in Gold Nanostars To Improve HER2-Targeted Cytotoxicity in HER2-Overexpressing Cancer Cells in the Presence of Serum Proteins".

This research from Dr. Souvik Mukherjee's lab at BRIC-NIBMG, in collaborations with CSIR NEERI, provides the first evidence from India that arsenic can alter not just physical health but also internal microbial ecosystems, with wide-reaching implications. The findings suggest that gut microbiome changes may serve as early biomarkers for arsenic exposure, even before symptoms appear. The observations show the urgent need to address chronic arsenic exposure not only as a toxicological concern but also as a microbial and metabolic health crisis. The insights from this study may help guide policy-making for the West Bengal government to mitigate health impacts of arsenic.

A new publication from the laboratory of G. S. Vinod Kumar (Scientist, BRIC-RGCB) appeared in ACS Applied Nano Materials. Title : In Vitro and In Vivo Evaluation of PCL–PEG Nanomicelles for Paclitaxel Drug Release to Treat Breast Cancer

Recent study by Prof. Sandeep Singh at BRIC-NIBMG using patient-derived cultures and validated in oral tumor samples at single cell level led to the discovery of stromal-fibroblast induced malignant cell plasticity. To translate; a small molecule inhibitor of a tyrosine kinase ‘Tie2’ reversed this reprogramming ability, and the identified gene expression modules were predictive of poor prognosis.

A new publication from the laboratory of Dr. Mahendran KR (Scientist, BRIC-RGCB) appeared in the journal "Small". The title of the manuscript is "A Dynamic Sugar-Selective Bacterial Nanopore for Targeted Antibiotic Transport".

India unlocks its genetic code! The GenomeIndia Project, a landmark effort by 20 institutions, has mapped the nation’s genetic diversity—powering personalized medicine, inclusive public health, and future-ready research. BRIC-NIBMG is one of collaborators of this multi-institutional project and has actively engaged in sample collection, sequence data generation and data analysis.

In the recent EMBO reports paper from BRIC-NIBMG, we have shown that MYC enhancer RNA (eRNA) dynamically interacts with YEATS2 protein and recruits YEATS2-containing ATAC complex on MYC promoter to induce MYC gene transcription in pancreatic cancer.

BRIC-National Institute of Biomedical Genomics is a key member of Asian Immune Diversity Atlas (AIDA). The study sequenced over 1.2 million blood cells from 619 healthy individuals in six different Asian groups (Chinese, Japanese, Korean, Indian, Malay, Thai) across five countries (Singapore, Japan, Korea, Thailand and India). This initiative will provide a healthy baseline for characterizing cell state changes in diverse immune-related diseases including infectious and auto-immune diseases and thus form a foundation for precision medicine for Asian populations.

Research study by Dr. Raghavendra PB group at (BRIC-NIBMG) represents the first novel Tertiary Lymphoid Organs (TLO’s) inflammatory landscape in the diabetic foot wound ulcers. Study findings document immunophenotyping for TLO inflammatory stratification for DFU disease pathogenesis, progression. TLO study might be effective unveil to shed light and develop modality with the targeted antimicrobial therapies, immunomodulatory intervention strategies for DFU complications.